KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Payables: 2009-2024

Historic Payables for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $2.2 billion.

  • Teva Pharmaceutical Industries' Payables fell 0.67% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 billion, marking a year-over-year decrease of 4.42%. This contributed to the annual value of $2.2 billion for FY2024, which is 15.33% down from last year.
  • Teva Pharmaceutical Industries' Payables amounted to $2.2 billion in FY2024, which was down 15.33% from $2.6 billion recorded in FY2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Payables peaked at $2.6 billion during FY2023, and registered a low of $1.7 billion during FY2021.
  • In the last 3 years, Teva Pharmaceutical Industries' Payables had a median value of $2.2 billion in 2024 and averaged $2.2 billion.
  • Its Payables has fluctuated over the past 5 years, first soared by 37.89% in 2023, then dropped by 15.33% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Payables (Yearly) stood at $1.8 billion in 2020, then declined by 3.99% to $1.7 billion in 2021, then rose by 11.92% to $1.9 billion in 2022, then surged by 37.89% to $2.6 billion in 2023, then dropped by 15.33% to $2.2 billion in 2024.